プロモーションスケジュール Reneo Pharmaceuticals, Inc.
詳細なスケジュール
簡易グラフ
会社について
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
IPO date |
2021-04-08 |
ISIN |
US75974E1038 |
Industry |
Biotechnology |
Sector |
Health Care |
Валюта |
usd |
Валюта отчета |
usd |
Сайт |
https://reneopharma.com
|
Цена ао |
1.65 |
1日あたりの価格変動: |
0% (1.82) |
週ごとの価格変動: |
0% (1.82) |
月ごとの料金変更: |
0% (1.82) |
3ヶ月間の価格変動: |
+9.64% (1.66) |
半年間の価格変動: |
+20.53% (1.51) |
年間の価格変動: |
+13.75% (1.6) |
3年間の価格推移: |
-73.55% (6.88) |
5年間の価格推移: |
0% (1.82) |
10年間の価格推移: |
0% (1.82) |
年初からの価格変動: |
0% (1.82) |
|
過小評価
名前 |
意味 |
学年 |
P/S |
0 |
0 |
P/BV |
0.4847 |
10 |
P/E |
0 |
0 |
EV/EBITDA |
-0.1973 |
0 |
合計: |
|
3.75 |
|
効率
名前 |
意味 |
学年 |
ROA, % |
-72.03 |
0 |
ROE, % |
-87.34 |
0 |
合計: |
|
0 |
|
|
配当金
名前 |
意味 |
学年 |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
合計: |
|
0 |
|
義務
名前 |
意味 |
学年 |
Debt/EBITDA |
-0.0118 |
10 |
合計: |
|
9.2 |
|
成長の衝動
名前 |
意味 |
学年 |
収益性 Revenue, % |
0 |
0 |
収益性 Ebitda, % |
433.98 |
10 |
収益性 EPS, % |
1476.7 |
10 |
合計: |
|
8 |
|
スーパーバイザー |
役職 |
支払い |
生年 |
Mr. Michael G. Grey |
Founder & Executive Chairman |
100k |
1953 (72 年) |
Mr. Gregory J. Flesher |
President, CEO & Director |
569.7k |
1970 (55 年) |
Mr. Michael P. Cruse |
Chief Operating Officer |
535.47k |
1972 (53 年) |
Ms. Jennifer P. Lam |
SVP of Finance & Administration and Principal Financial & Accounting Officer |
N/A |
|
Dr. Alejandro Dorenbaum M.D. |
Chief Medical Officer |
466.23k |
1961 (64 年) |